The media queen also confessed that she was reluctant to take a GLP-1 drug because she felt it was “the easy way out.” That ...

including several newly found conditions linked to the GLP-1 class of weight loss and diabetes drugs. However, the new study led by Ziyad Al-Aly, a physician-scientist at the Veterans Affairs St ...

Ozempic, a drug developed and approved for the treatment ... While exercise is the number 1 weight loss method according to ...

In July, the company changed tactics on its weight loss drug, cutting the daily dose from two to one. The company is currently engaged in clinical trials on danuglipron, with results expected to ...

Eli Lilly expects its experimental weight loss pill, orforglipron, to be approved as soon as early next year, CEO David Ricks told Bloomberg. Eli Lilly and Novo Nordisk, which dominate the market ...

Eli Lilly (NYSE:LLY) CEO Dave Ricks said Monday that the company's GLP-1 weight-loss pill orforglipron could receive FDA approval as soon as early 2026. In an interview with Bloomberg TV ...

It’s one of Europe’s largest ... the makers of the two most popular weight loss drugs, Ozempic and Wegovy. The company promises to offer less invasive pills, instead of injectables.